Structural insights and biomedical potential of IgNAR scaffolds from sharks
- PMID: 25523873
- PMCID: PMC4622739
- DOI: 10.4161/19420862.2015.989032
Structural insights and biomedical potential of IgNAR scaffolds from sharks
Abstract
In addition to antibodies with the classical composition of heavy and light chains, the adaptive immune repertoire of sharks also includes a heavy-chain only isotype, where antigen binding is mediated exclusively by a small and highly stable domain, referred to as vNAR. In recent years, due to their high affinity and specificity combined with their small size, high physicochemical stability and low-cost of production, vNAR fragments have evolved as promising target-binding scaffolds that can be tailor-made for applications in medicine and biotechnology. This review highlights the structural features of vNAR molecules, addresses aspects of their generation using immunization or in vitro high throughput screening methods and provides examples of therapeutic, diagnostic and other biotechnological applications.
Keywords: CDR, complementarity-determining region; HV, hypervariable region; IgNAR; IgNAR V domain, variable domain of IgNAR; IgNAR, immunoglobulin new antigen receptor; VH, variable domain of the heavy chain; VHH, variable domain of camelid heavy chain antibodies; VL, variable domain of the light chain; antibody technology; biologic therapeutic; heavy chain antibody; mAbs, monoclonal antibodies; scFv, single chain variable fragment; shark; single chain binding domain; vNAR, variable domain of IgNAR.
Figures
References
-
- Aggarwal RS. What's fueling the biotech engine-2012 to 2013. Nat Biotechnol 2014; 32:32-9; PMID:24406926; http://dx.doi.org/10.1038/nbt.2794 - DOI - PubMed
-
- Aggarwal SR. What's fueling the biotech engine-2011 to 2012. Nat Biotechnol 2012; 30:1191-7; PMID:23222785; http://dx.doi.org/10.1038/nbt.2437 - DOI - PubMed
-
- Buss NA, Henderson SJ, McFarlane M, Shenton JM, de Haan L. Monoclonal antibody therapeutics: history and future. Curr Opin Pharmacol 2012; 12:615-22; PMID:22920732; http://dx.doi.org/10.1016/j.coph.2012.08.001 - DOI - PubMed
-
- Reichert JM. Marketed therapeutic antibodies compendium. MAbs 2012; 4:413-5; PMID:22531442; http://dx.doi.org/10.4161/mabs.19931 - DOI - PMC - PubMed
-
- Reichert JM. Which are the antibodies to watch in 2013? MAbs 2013; 5:1-4; PMID:23254906; http://dx.doi.org/10.4161/mabs.22976 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources